Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL-108 in Mild Cognitive Impairment
NCT00422981Phase 2Completed
- Sponsor
- Allon Therapeutics Inc.
- Start
- Jan 2007
- Primary completion
- Jan 2008
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of davunetide in Mild Cognitive Impairment (MCI), sponsored by Allon Therapeutics Inc.. Started Jan 2007; status: completed.
02
Drugs
davunetide
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT00422981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00422981.